SCHEMBL3069287

SCHEMBL3069287

COc1ccc(Cn2nc(C)c(-c3ccc(C#N)c(Cl)c3)c2C)cc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
AR P10275 4/20 0.44
MAPT P10636 2/20 0.41
TP53 P04637 1/20 0.41
FNTA P49354 3/20 0.41
FNTB P49356 3/20 0.41
PGGT1B P53609 3/20 0.41
CACNA1H O95180 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
MEN1 O00255 2/20 0.38
HPGD P15428 2/20 0.38
KMT2A Q03164 2/20 0.38
USP2 O75604 2/20 0.38
HSD17B10 Q99714 2/20 0.38
ALDH1A1 P00352 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
S1PR1 P21453 1/20 0.38
PDE4A P27815 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3087463 0.89 CYP1A2 (0.47) KDM4ESMN1; SMN2ARFNTAFNTB
SCHEMBL3069345 0.87 AR (0.39) KDM4ELMNAARMAPTTP53
SCHEMBL3070056 0.87 ALDH1A1 (0.45) KDM4EARALDH1A1
SCHEMBL3070012 0.86 AR (0.50) KDM4ESMN1; SMN2ARMAPTPTGDR2
SCHEMBL3077429 0.86 AR (0.50) KDM4ESMN1; SMN2ARMAPTTP53
SCHEMBL3081376 0.85 AR (0.49) ARPTGDR2
SCHEMBL3086122 0.85 AR (0.46) LMNASMN1; SMN2ARFNTAFNTB
SCHEMBL3075912 0.84 AR (0.44) ARFNTAFNTBPGGT1BPTGDR2
SCHEMBL3081338 0.84 AR (0.43) KDM4EARMAPTMEN1HPGD
SCHEMBL3063842 0.84 AR (0.48) KDM4EARFNTAFNTBPGGT1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
EP-2194045-A1 SUBSTITUTED PYRAZOLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2010-06-09 EP disclosed
EP-2194045-A1 SUBSTITUTED PYRAZOLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2010-06-09 EP disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE AR, NR5A1, NR3C2 KDM4E 1414/4885LMNA 4608/4885SMN1; SMN2 4482/4885
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AR, NR5A1, NR3C2 KDM4E 1440/4885LMNA 4607/4885SMN1; SMN2 4488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.